These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17396166)

  • 1. Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101).
    Brawer MK
    Rev Urol; 2007; 9(1):1-8. PubMed ID: 17396166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
    Beer TM
    BJU Int; 2005 Sep; 96(4):508-13. PubMed ID: 16104901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
    J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Chi KN; Young J; Henner WD;
    Cancer; 2008 Jan; 112(2):326-30. PubMed ID: 17960793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
    J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy.
    Henner WD; Beer TM
    Rev Urol; 2003; 5 Suppl 3(Suppl 3):S38-44. PubMed ID: 16985949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
    Beer TM; Eilers KM; Garzotto M; Egorin MJ; Lowe BA; Henner WD
    J Clin Oncol; 2003 Jan; 21(1):123-8. PubMed ID: 12506180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
    Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
    Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
    Beer TM; Hough KM; Garzotto M; Lowe BA; Henner WD
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):49-55. PubMed ID: 11685729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
    Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
    BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of weekly high-dose calcitriol based therapy for prostate cancer.
    Beer TM
    Urol Oncol; 2003; 21(5):399-405. PubMed ID: 14670552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
    Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD
    J Clin Oncol; 2004 Jul; 22(13):2532-9. PubMed ID: 15226321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
    Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
    Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
    Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):62-6. PubMed ID: 11685731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
    J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
    Beer TM; Garzotto M; Henner WD; Eilers KM; Wersinger EM
    Br J Cancer; 2004 Oct; 91(8):1425-7. PubMed ID: 15467765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in management of advanced prostate cancer.
    Kantoff P
    Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
    Medioni J; Deplanque G; Ferrero JM; Maurina T; Rodier JM; Raymond E; Allyon J; Maruani G; Houillier P; Mackenzie S; Renaux S; Dufour-Lamartinie JF; Elaidi R; Lerest C; Oudard S
    Clin Cancer Res; 2014 Sep; 20(17):4471-7. PubMed ID: 25013124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.